Candel Therapeutics (CADL) Equity Ratio (2020 - 2025)

Candel Therapeutics has disclosed Equity Ratio across 6 years of filings, most recently posting 0.41 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.41, down 33.18% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.41 (down 33.18% YoY), and the FY2025 annual result was 0.41, down 33.18% from the prior year.
• Equity Ratio came in at 0.41 for Q4 2025 at Candel Therapeutics, down from 0.86 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q3 2025 to a low of 1.4 in Q2 2021.
• The 5-year median for Equity Ratio is 0.61 (2022), against an average of 0.37.
• Across the five-year window, Equity Ratio slumped 254.19% in 2024 and surged 326.1% in 2025, its largest moves.
• Candel Therapeutics' Equity Ratio stood at 0.72 in 2021, then decreased by 14.58% to 0.61 in 2022, then plunged by 49.63% to 0.31 in 2023, then surged by 100.64% to 0.62 in 2024, then slumped by 33.18% to 0.41 in 2025.
• The last three Equity Ratio figures came in at 0.41 (Q4 2025), 0.86 (Q3 2025), and 0.85 (Q2 2025), per Business Quant data.